Daily Science Journal (Feb. 13, 2008) — One drink of either red wine or alcohol slightly benefits the heart and blood vessels, but the positive effects on specific biological markers disappear with two drinks, say researchers at the Peter Munk Cardiac Centre of the Toronto General Hospital.

Researchers conducted a real-time study of thirteen volunteers to determine whether a red wine with a verified high polyphenol content differs from alcohol in its effects on specific markers associated with a greater risk of high blood pressure, coronary artery disease and heart failure.

A large number of population studies have shown a protective effect of light or moderate alcohol drinking against the risk of death and the development of heart disease. Many studies have also reported specific benefits of red wine.

Population surveys found lower rates of heart disease, despite high-fat diets, in some European countries where red wine was consumed regularly. Widely known at the French paradox, this has created a huge interest in exploring if and how red wine has a protective effect against heart disease.


However, the findings of this study* showed virtually identical effects of red wine and alcohol on the specific markers tested. After one drink of either red wine or alcohol, blood vessels were more “relaxed” or dilated, which reduced the amount of work the heart had to do. But, after two drinks, the heart rate, amount of blood pumped out of the heart, and action of the sympathetic nervous system all increased. At the same time, the ability of the blood vessels to expand in response to an increase in blood flow diminished. This counteracted the beneficial effect of one drink of red wine or alcohol.

“We had anticipated that many of the effects of one ethanol drink would be enhanced by red wine. What was most surprising was how similar the effects were of red wine and ethanol. Any benefits that we found were not specific to red wine,” said Dr. John Floras, Director of Cardiology Research at the Peter Munk Cardiac Centre, and at Mount Sinai Hospital, in whose laboratory the study was performed. However, Dr. Floras cautioned this study measured the effects of these drinks on one occasion only. The effects of daily wine or alcohol intake may be quite different.

The laboratory of Dr. Floras, who holds the Canada Research Chair in Integrative Cardiovascular Biology and is a Professor of Medicine at the University of Toronto, and a Career Investigator of the Heart and Stroke Foundation, is one of the few in the world equipped to measure simultaneously a broad spectrum of factors such as blood pressure, heart rate, sympathetic nerve firing and arterial diameter.

Healthy, non-smoking adults who were not heavy drinkers or total alcohol abstainers were studied. Participants attended three separate morning sessions during which “standard” drinks of red wine, ethanol or water were administered at random, single-blind, two weeks apart. A 4-oz glass of wine (120 ml), and a 1.5-oz (44 ml) shot of spirits is considered to be one standard drink. All blood alcohol levels alcoholic were below .08, the legal limit for drivers.

The Quality Assurance Laboratory of the Liquor Control Board of Ontario selected a moderately priced pinot noir with a verified high t-resveratrol content, a polyphenol compound found in plants, including red grapes, which exhibits antioxidant properties. Alcohol or substances in alcohol such as resveratrol may improve blood vessel function and also prevent platelets in the blood from sticking together, which may reduce clot formation and the risk of heart attack or stroke.

Select study findings:

One drink of either red wine or alcohol:

* Has no effect on heart rate, blood pressure or sympathetic nerve activity, which activates the “fight or flight” reaction and generally modulates heart rate and sets the diameter of blood vessels in order to redistribute blood;
* Dilates the brachial artery.

Two drinks of either alcohol or red wine:

* Increase sympathetic nerve activity, heart rate, and the amount of blood the heart pumps out, and also blunt the ability of the brachial artery to expand further in response to blood flow.
* Increases in heart rate and sympathetic nerve activity are recognized markers for hypertension (high blood pressure), heart failure and sudden death.

“Our findings point to a slight beneficial effect of one drink – be it alcohol or red wine – on the heart and blood vessels, whereas two or more drinks would seem to turn on systems that stress the circulation. If these actions are repeated frequently because of high alcohol consumption these effects may expose individuals to a higher risk of heart attacks, stroke or chronic high blood pressure,” noted Dr. Floras, adding that the American Heart Association (AHA) does not recommend that anyone start drinking alcohol to prevent heart disease. Reducing risk can be done using other methods such as exercise and following a healthy diet.

The study entitled “Dose-related effects of red wine and alcohol on hemodynamics, sympathetic nerve activity, and arterial diameter”, was published in the February edition of the American Journal of Physiology, Heart and Circulatory Physiology. This study was supported by the Heart and Stroke Foundation of Ontario, the Canadian Institutes of Health Research, and the Canada Research Chairs Program.

Adapted from materials provided by University Health Network, via Newswise.



Read the rest of this entry »

Daily Science Journal (Feb. 13, 2008) — A unique collaboration between scientists, public health workers and police has led to the arrest by the Chinese authorities of alleged traders of fake anti-malarial drugs in southern China and the seizure of a large quantity of drugs. The work, involving teams from across the globe, has highlighted both the growing threat posed by fake pharmaceuticals and the complexities of tracking down those responsible for the trade.

Counterfeit artesunate anti-malarial tablet with fake 'X-52' stamp as seen under UV light. (Credit: Newton PN, Fernandez FM, Plancon A, Mildenhall DC, Green MD,et al.)

Dubbed Operation Jupiter, the investigation was coordinated by the International Criminal Police Organisation (INTERPOL), the World Health Organization's Western Pacific Regional Office, and the Wellcome Trust-University of Oxford SE Asian Tropical Medicine Research Programme, in close cooperation with Chinese authorities. Scientists from 5 other laboratories analysed the composition of the fake drugs and their packaging.


Fake anti-malarial drugs are an increasingly serious problem, particularly in South-East Asia and Africa. In countries with a large burden of malaria, such as Myanmar (Burma), the Lao PDR, Cambodia and Viet Nam, as many as half of all artesunate tablets -- one of the most effective anti-malarial drugs -- is counterfeit.

Most of the fakes examined as part of Operation Jupiter contained no artesunate, and some contained a wide range of potentially toxic wrong active ingredients. Also of grave concern was the fact that counterfeiters sometimes included dangerously small amounts of artesunate in the tablets. This may be done to foil screening tests of drug quality, but these doses are too low to be efficacious, yet high enough to contribute to malaria parasites becoming resistant to this class of drugs.

"Artesunate, as part of artemisinin-based combination therapy, is vital for malaria treatment and is one of the most effective weapons we have against this terrible scourge," says Dr Paul Newton of the Wellcome Trust-University of Oxford SE Asian Tropical Medicine Research Programme. "Those who make fake anti-malarials have killed with impunity, directly through the criminal production of a medicine lacking active ingredients and by encouraging drug resistance to spread. If malaria becomes resistant to artesunate, the effect on public health in the tropics will be catastrophic."

In addition to analysing the chemistry of the samples, researchers used a technique known as forensic palynology to study pollen contamination within the fake tablets with the aim of tracking down the likely location of manufacture. The pollen evidence suggested that at least some of the counterfeit artesunate came from southern China, and this was supported by examination of the mineral calcite, found in some of the samples.

Armed with these findings by INTERPOL, Chinese authorities arrested a suspect in China's Yunnan Province in 2006. He is alleged to have traded 240,000 blisterpacks of counterfeit artesunate, enough to "treat" almost a quarter of a million adults with a medicine with no activity against a potentially fatal disease. Whilst the Chinese authorities were able to seize 24,000 of these packs, the remainder are alleged to have been sold at crossings on the border of Yunnan and Myanmar (Burma), accounting for almost a half of all blisterpacks of artesunate sold to the region.

The work of the Jupiter group highlights the need for more to be done internationally to support countries with a high prevalence of counterfeit anti-malarials in their attempts to combat this severe but under-recognised public health problem.

"Criminal investigations and legal action are important in disrupting and inhibiting the trade in fake medicines, but to be effective these will require financial support and resources," says Dr Newton. "Forensic tools may make it easier to identify the fake drugs and allow over-stretched police forces to focus on objective leads, greatly increasing the risks to counterfeiters of being caught. However, there are very few laboratories with the resources to perform detailed forensic chemistry or pollen analysis of fakes, particularly in the countries where they are most needed."

Journal citation: Newton PN, Fernandez FM, Plancon A, Mildenhall DC, Green MD,et al. (2008) A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 5(2): e32.

Adapted from materials provided by Wellcome Trust.



Read the rest of this entry »

Daily Science Journal (Feb. 13, 2008) — The 24th shuttle flight to the International Space Station, STS-122, delivers Columbus, the European Space Agency's new laboratory. Columbus will be installed on Harmony Node 2.

European astronaut and station flight engineer Leopold Eyharts photographs the inside of the new Columbus laboratory. In the foreground is European astronaut and mission specialist Hans Schlegel. (Credit: NASA TV)

European astronaut and station flight engineer Leopold Eyharts got a look inside the new Columbus laboratory around 9 a.m. EST February 12. Official ingress is scheduled to occur at 2:55 p.m after preliminary outfitting of the new lab.


Supplies and equipment will be transferred into the European Space Agency’s Columbus laboratory. Three of the laboratory module’s five payload racks also are scheduled for relocation Feb. 12. Expedition 16 crew members Leopold Eyharts and Peggy Whitson will be the first to enter Columbus.

Later in the day, STS-122 Mission Specialists Rex Walheim and Hans Schlegel will camp out in the station’s Quest Airlock in preparation for the Feb. 13 spacewalk, scheduled for 9:35 a.m. EST.

On Feb 11, astronauts used the station’s robotic arm to connect Columbus to the orbital outpost and Walheim and Mission Specialist Stanley Love conducted the first of three scheduled STS-122 spacewalks. Among other tasks, the spacewalkers prepared the new module for its installation.

Adapted from materials provided by National Aeronautics And Space Adminstration.



Read the rest of this entry »

Daily Science Journal (Feb. 13, 2008) — A new type of membrane, developed by scientists of the University of Twente in The Netherlands, can stand high temperatures for a long period of time. This ‘molecular sieve’ is capable of removing water out of e.g. solvents and biofuels. It is a very energy efficient alternative to existing techniques like distillation.

The cylinder is the carrier of a hybrid membrane: a layer of about 100 nanometer thickness. The insert shows a close-up of the layer showing the organic links and pores. From the left of the tube, only water molecules leave the sieve. (Credit: Image courtesy of University of Twente)

Even after testing during 18 months, the new membranes prove to be highly effective, while having continuously been exposed to a temperature of 150 ºC. Existing ceramic and polymer membranes will last considerably shorter periods of time, when exposed to the combination of water and high temperatures. The scientists managed to do this using a new ‘hybrid’ type of material combining the best of both worlds of polymer and ceramic membranes. The result is a membrane with pores sufficiently small to let only the smallest molecules pass through.


Ceramic membranes, made of silica, degrade because they react with water and steam. In the new membrane, part of the ceramic links is therefore replaced by organic links. By doing this, water doesn’t have the chance to ‘attack’ the membranes. Manufacturing the new hybrid membranes is simpler than that of ceramic membranes, because the material is flexible and will not show cracks. What they have in common with ceramic membranes is the rapid flow: an advantage of this is that the membrane surface can be kept small.

The hybrid membranes are suitable for ‘drying’ solvents and biofuels, an application for which there is a large potential market worldwide. The main advantage of membrane technology is that it consumes far less energy than common distillation techniques.

The scientists also foresee opportunities in separating hydrogen gas from gas mixtures. This implies a broad range of applications in sustainable energy. Apart from that, the hybrid membranes are suitable for desalinating water. Using a hybrid membrane that is much smaller than the current polymer membranes, the same result can be achieved.

The results have been achieved in a close cooperation of scientists from the Inorganic Materials Science Group of the MESA+ Institute for Nanotechnology (UT), the Energy Efficiency in Industry department of ECN and the University of Amsterdam. The invention has been patented worldwide.

The article ‘Hybrid ceramic nanosieves: stabilizing nanopores with organic links’ by Hessel Castricum, Ashima Sah, Robert Kreiter, Dave Blank, Jaap Vente and André ten Elshof has been published in Chemical Communications (ChemComm) of the Royal Society of Chemistry in de UK.

Adapted from materials provided by University of Twente.



Read the rest of this entry »

Daily Science Journal (Feb. 13, 2008) — If humans had see-through skin like a jellyfish, spotting disease like cancer would be a snap: Just look, and see a tumor form or grow.

Diagram of chicken breast tissue (approximately 250 microns thick) with photo-refractive crystal to counteract the scattering of light and remove the distortion it creates in images. The lower diagram would show the clearest image. (Credit: Caltech Biophotonics Laboratory)

But humans, of course, are not remotely diaphanous. "The reason a person is not transparent is that their tissues are highly scattering," sending light waves careening through the tissue instead of straight through, as they would through the tissue of that jellyfish, explains Changhuei Yang of the California Institute of Technology.

This scattering, in addition to rendering all of us opaque, makes the detection of disease a much trickier issue, requiring a host of diagnostic tests and procedures. But not, perhaps, for much longer, thanks to a new optical trick developed by Yang, an assistant professor of electrical engineering and bioengineering, and his colleagues, that counteracts the scattering of light and removes the distortion it creates in images.


It is well known that light scattering in a material is not exactly the random and unpredictable process one might imagine. In fact, scattering is deterministic, which means that the path that a beam of light takes as it traverses a particular slice of tissue and bounces and rebounds off of individual cells, is entirely predictable; if you again bounce light through that same swath of cells, it will scatter in exactly the same way.

The process is even reversible; if the individual photons of light that scattered through the tissue could be collected and sent back through the tissue, they'd bounce back along the same path and converge at the original spot from which they were sent. "The process is similar to the scattering of billiard balls on a pool table. If you can precisely reverse the paths and velocities of the billiard balls, you can cause the billiard balls to reassemble themselves into a rack," Yang explains.

Yang, along with his colleagues at Caltech, École Polytechnique Fédérale de Lausanne in Switzerland, and MIT, exploited this phenomenon to offset the murky nature of our tissues.

Their technique, called turbidity suppression by optical phase conjugation (TSOPC), is surprisingly simple. The scientists used a holographic crystal to record the scattered light pattern emerging from a 0.46-mm-thick piece of chicken breast. They then holographically played the pattern back through the tissue section to recover the original light beam. "This is similar to grabbing hold of the direction of time flow and turning it around; the time-reversed photons must retrace their trajectories through the tissue," Yang says. "The task is formidable though, as this is comparable to starting with a rack of 10 to the 18th power billiard balls (or photons), scattering them around the table, and attempting to reassemble them into a rack."

"Until we did this study, it wasn't clear that the effect will be observable with biological tissues. We were pleasantly surprised that the effect was readily observable and remarkably robust," Yang says. "This study opens up numerous possibilities in the use of optical time reversal in biomedicine."

One possible use of the technique is in photodynamic therapy, in which a highly focused beam of light is aimed at cancerous cells that have absorbed cell-killing light-sensitive compounds. When the light hits the cells, the compounds are activated and destroy the cells. Photodynamic therapy is most effective in treating cancers on the skin surface. Yang's technique, however, offers a way to concentrate light onto cancer-killing compounds located more deeply within tissue.

Yang's idea is to inject strongly light-scattering particles that are coated with light-activated cancer-killing drugs into diseased tissue. Shine a beam of light into the tissue, and it would be reflected off the scattering compounds as it bounces through the tissue. Some of the scattered light would return to the source, where it could be recorded as a hologram.

This hologram would contain information about the path that the scattered light took through the tissue, and, in effect, describe the optimal path BACK toward the light-scattering molecule--and the cancer-killing compounds. Playing back the signal with a stronger burst of light will then activate the therapeutic drugs, which kill the cancer cells.

In addition, the technique could offer a way to power miniature implants buried deep within tissues. "If you take a quick survey of what is out there at present, you will see that implants are fairly large," Yang says. "For example, a pacemaker is about the size of a cell phone. Why are they so big? A large part of the reason is because they need to carry their own power sources."

The key to making smaller implants, then--say, the size of a pen tip--is to eliminate the power sources. "I think implants that carry photovoltaic receivers are particularly promising," he says. "The effect can be applied to tailor light-delivery mechanisms to efficiently channel light into tissues and onto these implants."

A study describing the process appears in the February issue of the journal Nature Photonics. Zahid Yaqoob, a postdoctoral fellow in electrical engineering at Caltech, performed most of the experiments reported in the paper. The other authors of the paper are Demetri Psaltis, professor of optics and dean of engineering, École Polytechnique Fédérale de Lausanne in Switzerland, and Michael S. Feld, a professor of physics at MIT.

Adapted from materials provided by California Institute of Technology.



Read the rest of this entry »

Daily Science Journal (Feb. 12, 2008) — Turning native ecosystems into "farms" for biofuel crops causes major carbon emissions that worsen the global warming that biofuels are meant to mitigate, according to a new study by the University of Minnesota and the Nature Conservancy.

Aerial view of farmland in Indonesia. The conversion of peatlands for palm oil plantations in Indonesia ran up the greatest carbon debt, one that would require 423 years to pay off. (Credit: iStockphoto)

The carbon lost by converting rainforests, peatlands, savannas, or grasslands outweighs the carbon savings from biofuels. Such conversions for corn or sugarcane (ethanol), or palms or soybeans (biodiesel) release 17 to 420 times more carbon than the annual savings from replacing fossil fuels, the researchers said. The carbon, which is stored in the original plants and soil, is released as carbon dioxide, a process that may take decades. This "carbon debt" must be paid before the biofuels produced on the land can begin to lower greenhouse gas levels and ameliorate global warming.


The conversion of peatlands for palm oil plantations in Indonesia ran up the greatest carbon debt, one that would require 423 years to pay off. The next worst case was the production of soybeans in the Amazon, which would not "pay for itself" in renewable soy biodiesel for 319 years.

"We don't have proper incentives in place because landowners are rewarded for producing palm oil and other products but not rewarded for carbon management," said University of Minnesota Applied Economics professor Stephen Polasky, an author of the study. "This creates incentives for excessive land clearing and can result in large increases in carbon emissions.

"This research examines the conversion of land for biofuels and asks the question 'Is it worth it?'," said lead author Joe Fargione, a scientist for The Nature Conservancy. "And surprisingly, the answer is no."

Fargione began the work as a University of Minnesota postdoctoral researcher with Polasky, Regents Professor of Ecology David Tilman; he completed it after joining the Nature Conservancy. They, along with university researchers Jason Hill and Peter Hawthorne, also contributed to the work.

"If you're trying to mitigate global warming, it simply does not make sense to convert land for biofuels production," said Fargione. "All the biofuels we use now cause habitat destruction, either directly or indirectly. Global agriculture is already producing food for six billion people. Producing food-based biofuel, too, will require that still more land be converted to agriculture."

These findings coincide with observations that increased demand for ethanol corn crops in the United States is likely contributing to conversion of the Brazilian Amazon and Cerrado (tropical savanna). American farmers traditionally rotated corn crops with soybeans, but now they are planting corn every year to meet the ethanol demand and Brazilian farmers are planting more of the world's soybeans. And they're deforesting the Amazon to do it.

The researchers also found significant carbon debt in the conversion of grasslands in the United States and rainforests in Indonesia.

Researchers did note that some biofuels do not contribute to global warming because they do not require the conversion of native habitat. These include waste from agriculture and forest lands and native grasses and woody biomass grown on marginal lands unsuitable for crop production. The researchers urge that all fuels be fully evaluated for their impacts on global warming, including impacts on habitat conversion.

"Biofuels made on perennial crops grown on degraded land that is no longer useful for growing food crops may actually help us fight global warming," said Hill. "One example is ethanol made from diverse mixtures of native prairie plants. Minnesota is well poised in this respect."

"Creating some sort of incentive for carbon sequestration, or penalty for carbon emissions, from land use is vital if we are serious about addressing this problem," Polasky said.

"We will need to implement many approaches simultaneously to solve climate change. There is no silver bullet, but there are many silver BBs," said Fargione. "Some biofuels may be one silver BB, but only if produced without requiring additional land to be converted from native habitats to agriculture."

The work will be published in Science later this month and will be posted online Thursday, Feb. 7.

The work was supported by the University of Minesota's Initiative for Renewable Energy and the Environment and the National Science Foundation.

Adapted from materials provided by University of Minnesota.



Read the rest of this entry »

Daily Science Journal (Feb. 12, 2008) — A new study in macaques suggests that antiretroviral drugs used to treat HIV could also protect people from getting the AIDS virus, especially if two drugs are taken in combination before exposure to the virus occurs.

A new study in macaques suggests that antiretroviral drugs used to treat HIV could also protect people from getting the AIDS virus, especially if two drugs are taken in combination before exposure to the virus occurs. (Credit: iStockphoto/Claire George)

The study found that macaques which were repeatedly exposed to SHIV (a virus closely related to HIV) but received antiretroviral drugs were less likely to become infected than exposed macaques that received no anti-HIV medication. The best protection was seen in macaques that had received a combination of two drugs. The study, led by José Gerardo García-Lerma and Walid Heneine from the US Centers for Disease Control and Prevention, is the culmination of a series of experiments designed to show how similar studies in humans -- some of which are planned and in progress -- can be optimally designed.


Although HIV treatment has rapidly advanced since the introduction of antiretroviral drugs in the 1990s, the absence of an effective vaccine means the virus continues to spread, infecting 2.5 million people each year. Pre-exposure prophylaxis (PrEP) -- the prevention of infection by treating people with drugs before they are exposed to the germ in question -- is often used to prevent malaria, but has not yet been shown to be effective against sexual transmission of HIV.

To simulate a common route of HIV transmission in humans, the researchers exposed the macaques to low weekly doses of SHIV that were given rectally. Five groups of macaques were all exposed to the virus in the same way, but they were given different dosages and combinations of antiretroviral drugs. Three groups received drugs daily: the first was only injected with one anti-HIV drug, emtricitabine (FTC); the second group received a daily dose of this drug by mouth in combination with an oral form of another anti-HIV drug called tenofovir; the third was injected with FTC and a high dose of tenofovir every day. A fourth group was also injected with FTC and a high dose of tenofovir, but macaques in this group were only treated shortly before and after the weekly exposures to HIV. For comparison a fifth group of macaques received no anti-HIV drugs.

The results showed that macaques from any of the four groups that received drugs were less likely to become infected than those in the fifth (control) group. All of the macaques receiving the combination of both FTC and the high dosage of tenofovir were protected from infection -- whether they were from the group that received these drugs daily, or only around the time of exposure to infection. The results suggest that higher doses and combinations of drugs worked better than single or low doses, and also that PrEP may not need to be taken every day to be effective.

The researchers also observed some risks that emphasize the need for careful design of human PrEP studies. They found some viral resistance to one of the drugs, FTC, in macaques that became infected. In addition, doses of tenofovir that resulted in maximum protection for macaques are higher than would be safe in humans.

In a related perspective article, Myron Cohen and Angela Kashuba from the University of North Carolina (Chapel Hill, NC, USA), uninvolved with the study, note that the results "highlight an exciting and potentially important use" of antiretroviral drugs to prevent sexual transmission of HIV.

Journal citation: García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong M, et al. (2008) Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5(2): e28. doi:10.1371/journal.pmed.0050028 http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050028

Adapted from materials provided by Public Library of Science, via EurekAlert!, a service of AAAS.



Read the rest of this entry »

Daily Science Journal (Feb. 12, 2008) — Few modern animals are as deserving of the title “living fossil” as the lowly horseshoe crab. Seemingly unchanged since before the Age of Dinosaurs, these venerable sea creatures can now claim a history that reaches back almost half-a billion years.

Lunataspis aurora - fossil paratype specimen (about 25 mm wide) beside the dried carapace of a young modern horseshoe crab. (Credit: Left image courtesy of G. Young, The Manitoba Museum; right, D. Rudkin, Royal Ontario Museum)

In a collaborative research article published recently in the British journal Palaeontology, a team of Canadian scientists revealed rare new horseshoe crab fossils from 445 million year-old Ordovician age rocks in central and northern Manitoba, which are about 100 million years older than any previously known forms.


Palaeontologist Dave Rudkin from the Royal Ontario Museum, with colleagues Dr. Graham Young of The Manitoba Museum (Winnipeg) and Dr. Godfrey Nowlan at the Geological Survey of Canada (Calgary), gave their remarkable new fossils the scientific name Lunataspis aurora, meaning literally “crescent moon shield of the dawn” in reference to their shape, geological age and northerly discovery sites. Although they are more “primitive” in several aspects than other known horseshoe crabs, their resemblance to living forms is unmistakable.

The fossil horseshoe crabs were recovered in the course of fieldwork studies on ancient tropical seashore deposits, providing yet another important link to their modern descendants that are today found along warmer seashores of the eastern United States and the Indian Ocean.

This is particularly significant, explains Rudkin. “Understanding how horseshoe crabs adapted to this ecological niche very early on, and then remained there through thick and thin, can give us insights into how ocean and shoreline ecosystems have developed through deep time.”

Today, marine shorelines worldwide are being threatened by human activity, and although some horseshoe crab populations are endangered, their enviably long record on Earth indicates that they have successfully weathered many previous crises, including the mass extinction that saw the demise of the dinosaurs and many other life forms 65 million years ago.

“We do need to be concerned about horseshoe crabs and many of the other unusual life forms found on marine shores,” said Dr. Young. “Nevertheless, we can also be mildly optimistic that some of these things have demonstrated a toughness that may allow them to survive our abuse of these environments.”

Living horseshoe crabs are extensively studied, especially in the fields of ecology and medical research. The exciting discovery of these unusual early fossil relatives adds a new introductory chapter to their remarkable story.

David Rudkin is Assistant Curator in the Department of Natural History (Palaeobiology) at the Royal Ontario Museum, and holds an appointment to the Department of Geology, University of Toronto, as a Lecturer in palaeontology. Rudkin joined the former Department of Invertebrate Palaeontology at the ROM in 1975 and began working on fossils from the Burgess Shale in British Columbia.

Adapted from materials provided by Royal Ontario Museum.



Read the rest of this entry »

Daily Science Journal (Feb. 11, 2008) — WHO has released new data showing that while progress has been made, not a single country fully implements all key tobacco control measures, and outlined an approach that governments can adopt to prevent tens of millions of premature deaths by the middle of this century. Unless urgent action is taken, tobacco could kill one billion this century.

Cigarette butts. Unless urgent action is taken, tobacco could kill one billion this century, WHO report warns. (Credit: iStockphoto/James Curtis)

Current status of tobacco-related deaths
  • 100 million dead in the 20th century
  • Currently 5.4 million deaths every year
Unless urgent action is taken
  • By 2030, there will be more than 8 million deaths every year
  • By 2030, more than 80% of tobacco deaths will be in developing countries
  • One billion estimated deaths during the 21st century


In a new report which presents the first comprehensive analysis of global tobacco use and control efforts, WHO finds that only 5% of the world’s population live in countries that fully protect their population with any one of the key measures that reduce smoking rates. The report also reveals that governments around the world collect 500 times more money in tobacco taxes each year than they spend on anti-tobacco efforts. It finds that tobacco taxes, the single most effective strategy, could be significantly increased in nearly all countries, providing a source of sustainable funding to implement and enforce the recommended approach, a package of six policies called MPOWER.

“While efforts to combat tobacco are gaining momentum, virtually every country needs to do more. These six strategies are within the reach of every country, rich or poor and, when combined as a package, they offer us the best chance of reversing this growing epidemic,” said Dr Margaret Chan, Director-General of WHO. Dr Chan launched the WHO Report of the Global Tobacco Epidemic at a news conference with New York Mayor Michael Bloomberg. Bloomberg Philanthropies helped fund the report.

“The report released today is revolutionary,” Mayor Bloomberg said. “For the first time, we have both a rigorous approach to stop the tobacco epidemic and solid data to hold us all accountable. No country fully implements all of the MPOWER policies and 80% of countries don’t fully implement even one policy. While tobacco control measures are sometimes controversial, they save lives and governments need to step up and do the right thing.”

The six MPOWER strategies
  • Monitor tobacco use and prevention policies
  • Protect people from tobacco smoke
  • Offer help to quit tobacco use
  • Warn about the dangers of tobacco
  • Enforce bans on tobacco advertising, promotion and sponsorship
  • Raise taxes on tobacco
The report also documents the epidemic's shift to the developing world, where 80% of the more than eight million annual tobacco-related deaths projected by 2030 are expected to occur.

This shift, the report says, results from a global tobacco industry strategy to target young people and adults in the developing world, ensuring that millions of people become fatally addicted every year. The targeting of young women in particular is highlighted as one of the “most ominous potential developments of the epidemic’s growth".

The global analysis, compiled by WHO with information provided by 179 Member States, gives governments and other groups a baseline from which to monitor efforts to stop the epidemic in the years ahead. The MPOWER package provides countries with a roadmap to help them meet their commitments to the widely embraced global tobacco treaty known as the WHO Framework Convention on Tobacco Control, which came into force in 2005.

WHO is also working with global partners to scale up the help that can be offered to countries to implement the strategies.

Dr Douglas Bettcher, Director of WHO’s Tobacco Free Initiative, said the six MPOWER strategies would create a powerful response to the tobacco epidemic. “This package will create an enabling environment to help current tobacco users quit, protect people from second-hand smoke and prevent young people from taking up the habit,” he said.

Other key findings in the report
  • Only 5% of the global population is protected by comprehensive national smoke-free legislation and 40% of countries still allow smoking in hospitals and schools;
  • Only 5% of the world’s population lives in countries with comprehensive national bans on tobacco advertising and promotion;
  • Just 15 countries, representing 6% of the global population, mandate pictorial warnings on tobacco packaging;
  • Services to treat tobacco dependence are fully available in only nine countries, covering 5% of the world’s people;
Tobacco tax revenues are more than 4000 times greater than spending on tobacco control in middle-income countries and more than 9000 times greater in lower-income countries. High- income countries collect about 340 times more money in tobacco taxes than they spend on tobacco control.

PDF of full report: http://www.who.int/entity/tobacco/mpower/mpower_report_full_2008.pdf

Adapted from materials provided by World Health Organization.




Read the rest of this entry »

Daily Science Journal (Feb. 11, 2008) — In a study of pregnant women, those with pregnancy-induced high blood pressure were found to have higher levels of a peptide that raises blood pressure in the pieces of tissue linking mother and fetus, according to researchers at Wake Forest University Baptist Medical Center. The finding, reported online in the journal Hypertension, may help explain how the disorder develops.

Preeclampsia, or high blood pressure induced by pregnancy, affects 7 to 10 percent of pregnancies in the United States and is the second-leading cause of maternal mortality. It is the leading cause of pre-term delivery and contributes significantly to stillbirths and death in newborns.

The researchers found that in women with preeclampsia, levels of angiotensin II (Ang II), a hormone that constricts blood vessels and causes blood pressure to rise, was doubled in the chorionic villi, part of the placenta that links mother and fetus and supplies food and oxygen.


"This finding may be part of the preeclampsia puzzle," said Lauren Anton, a graduate student who is first author on the research. "Anything that gets us closer to understanding this disease is important because there is no treatment and no cure and women are still delivering babies too early."

The researchers theorize that Ang II may restrict the fetal vessels that lie within the chorionic villi, which not only raises blood pressure, but also lowers oxygen and nutrient flow to the baby and may result in lower birth weight and other complications of preeclampsia.

The study involved 21 women with preeclampsia and 25 women without the disorder. After delivery, tissue sections were taken from the center of the placenta for analysis.

Ang II is part of the renin angiotensin system (RAS) that regulates blood pressure. The system has been shown to play an important role in preeclampsia. However, changes in the system also occur in women who don't develop the condition. In normal pregnancies, estrogen causes increased levels of several hormones, including Ang II, in the blood. Despite the increase of Ang II in the blood during pregnancy, most women do not develop preeclampsia.

This the first study to demonstrate that all three peptides involved in the RAS are found in the chorionic villi of both normal and preeclamptic women. And, it was the first to show that levels of Ang II are higher in the chorionic villi of women with preeclampsia.

"This implies that local tissues are contributing to the problem," said K. Bridget Brosnihan, Ph.D., senior researcher, who has been studying preeclampsia for 12 years. "The hormone is remarkably elevated in this relatively small tissue, which implies that it has an important role in the development of preeclampsia."

The researchers hope that the findings may one day lead to treatment for preeclampsia.

ACE inhibitor drugs are currently used to lower Ang II in non-pregnant women with hypertension, but these drugs cannot be given to pregnant women. The study authors suggest that other therapies aimed at regulating blood pressure might be beneficial if they target the chorionic villi rather than the system as a whole. They are currently working to determine if growth factors that cause the placenta's blood supply to develop may also be regulated by the increase in Ang II.

The study was supported, in part, by the National Institutes of Health and the American Heart Association. It was published in the Go Red issue of Hypertension that is dedicated to women's cardiovascular health.

Co-researchers are David Merrill, M.D., Ph.D., Liomar Neves, Ph.D., Kathryn Stovall, B.S., Patricia Gallagher, Ph.D., Debra Diz, Ph.D., Cheryl Moorefield, R.N., Courtney Gruver, R.N., and Carlos Ferrario, M.D., all with Wake Forest.

Adapted from materials provided by Wake Forest University Baptist Medical Center, via EurekAlert!, a service of AAAS.



Read the rest of this entry »

Daily Science Journal (Feb. 11, 2008) — The U.S. Food and Drug Administration has notified the public that Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) have been linked in some cases to adverse reactions, including respiratory failure and death, following treatment of a variety of conditions using a wide range of doses.

In an early communication based on the FDA's ongoing safety review, the agency said the reactions may be related to overdosing. There is no evidence that these reactions are related to any defect in the products.


The adverse effects were found in FDA-approved and nonapproved usages. The most severe adverse effects were found in children treated for spasticity in their limbs associated with cerebral palsy. Treatment of spasticity is not an FDA-approved use of botulism toxins in children or adults.

The adverse reactions appear to be related to the spread of the toxin to areas distant from the site of injection, and mimic symptoms of botulism, which may include difficulty swallowing, weakness and breathing problems.

The FDA is not advising health care professionals to discontinue prescribing these products.

The agency is currently reviewing safety data from clinical studies submitted by the drugs' manufacturers, as well as post-marketing adverse event reports and medical literature. After completing a review of the data, the FDA will communicate to the public its conclusions, resulting recommendations, and any regulatory actions.

Adapted from materials provided by US Food And Drug Administration.



Read the rest of this entry »

Daily Science Journal (Feb. 11, 2008) — John Wesley Powell wrote in 1895: “...what a conflict of water and fire there must have been [in western Grand Canyon]! Just imagine a river of molten rock running down over a river of melted snow.”

Toroweap Point in Grand Canyon national park. (Credit: iStockphoto/Natalia Bratslavsky)

Over 110 years later, a synthesis of new and existing dates on these lava flows shows that many are significantly younger than initially thought and all are less than 725 thousand years old. The geochronology data indicates four major episodes when lava flows either erupted into the canyon or flowed over the rim into it: 725-475 thousand years ago (ka), 400-275 ka, 225-150 ka, and 150-75 ka.

These flows formed lava dams in western Grand Canyon that had dramatic impact on the Colorado River.


This paper* presents light detection and ranging (lidar) data to establish the elevations of the tops and bottoms of basalt flow remnants along the river corridor. These data show the original extent of now-dissected intra-canyon flows and aid in correlation of flow remnants.

From 725 to 475 ka, volcanism built a high edifice within Grand Canyon in the area of the Toroweap fault, with dike-cored cinder cones on both rims and within the canyon itself. These large-volume eruptions helped drive the far-traveled basalt flows which flowed down-canyon over 120 km. A second episode of volcanism, from 400 to 275 ka, built a 215-m-high dam along the Hurricane fault, about 15 km downstream.

The ca. 200 and 100 ka flows (previously mapped as Gray Ledge) were smaller flows and lava cascades that entered the canyon from the north rim between the Toroweap and Hurricane faults.

The combined results suggest a new model for the spatial and temporal distribution of volcanism in Grand Canyon in which composite lava dams and edifices were generally leaky in proximal areas.

Available data suggest that the demise of volcanic edifices may have involved either large outburst-flood events or normal fluvial deposition at times when the river was established on top of basalt flows. These data highlight complex interactions of volcanism and fluvial processes in this classic locality.

This research, authored by Ryan Crow (University of New Mexico) et al. was published in the February issue of Geosphere, published by the Geological Society of America.

Adapted from materials provided by Geological Society of America.



Read the rest of this entry »

Daily Science Journal (Feb. 10, 2008) — For Kansas State University physics professor Uwe Thumm, confirmation of a theory about the behavior of small molecules became music to his ears -- literally. He and colleagues in Heidelberg, Germany, have shown how a hydrogen molecule responds to laser pulses by using the changing musical chord created by the molecule's vibrational motion.

Researchers in Heidelberg visualized the development over time of molecular resonance. The distance between the two nuclei (R) in the heavy hydrogen (deuterium) ion D2+ is plotted against the time. After approximately 100 femtoseconds, the wave packet, i.e. the location of the nuclei, starts to become hazy, after 400 femtoseconds there is a "revival" and the wave packet is put back together again. (Credit: Max Planck Institute for Nuclear Physics)

Thumm is a member of K-State's J.R. Macdonald Laboratory, where he is among several researchers who work on the properties and behavior of atoms and small molecules.

For decades, researchers had used the Macdonald Laboratory to make atoms and molecules collide with particles. Thumm said much of what scientists know about atoms and molecules is based on such collision experiments. To predict and explain what happens in these collisions, a large group of experimental physicists works closely with Thumm and two other theorists. The theorists use computers, make models and crunch numbers with the hope of producing results that are compatible with what experiments show.


Thanks to improvements in laser technology, around 1999 the Macdonald Laboratory researchers realized that they could transfer a lot of their expertise in atomic collisions to study in detail what happens when atoms and molecules get irradiated by very intense laser light. The new laser systems in the laboratory offer some advantages over the big particle accelerators, Thumm said. The laser pulses offer more control and can be made so short that the researchers now routinely observe the motion of nuclei inside small molecules in time. In addition, the laser pulses' peak intensity is enormous and would equal all of the sun's light focused onto a small spot of the size of a postage stamp or smaller.

Motivated by these opportunities, Thumm and his colleagues became curious about figuring out what would happen if the smallest and simplest molecule, hydrogen, were exposed to such ultra short and intense laser pulses. Together with his postdoctoral collaborator Bernold Feuerstein, Thumm developed a model and did calculations to determine how laser pulses influence the motion of the two protons in the hydrogen molecule.

"The short answer is that the laser pulse either makes the molecules vibrate more violently or blows them apart," Thumm said. He said this wasn't surprising because in the hydrogen molecule, two protons are connected by two electrons that function like a spring. When hit with the laser pulses, the protons oscillate back and forth.

Although this model may be easy to imagine on a large scale, Thumm said particles behave differently at the quantum level. This means that determining the locations of these oscillating protons isn't easy. Thumm described determining the protons' movements after being hit with the laser like what happens if you drop a marble in a bathtub. Looking at the circular ripples of water in the center of the tub, it's pretty easy to tell where the marble was dropped in. But when those ripples bounce off the sides of the tub, the wave pattern changes shape, and it becomes harder to tell where the marble was dropped. The wave gets delocalized. Thumm said the same thing happens to the protons not in a matter of seconds, but in a matter of femtoseconds -- that's a billionth of a millionth of a second. After about 60 femtoseconds, it's impossible to tell where the protons are.

"You quickly loose track of what the distance between the two protons is," Thumm said." All you can say is that they have a certain likelihood of being at a certain distance. This is in agreement with the bathtub experiment: Seconds after the marble was dropped, you can't tell where exactly it plunged in."

But things work differently at the quantum level, and the researchers were surprised that about 600 femtoseconds after being hit with the laser, the distance between the protons again becomes well defined. "We call this a revival of the original motion of the protons," Thumm said. "It's not going to happen in the bathtub, but it happens at the quantum level."

Thumm and Feuerstein published their theoretical prediction in 2003. Thumm said that they were pleasantly surprised when experiments at the Max-Planck Institute in Heidelberg, Germany, in 2006 confirmed the revival described in their model. "The agreement between the new experiments and our model was almost perfect and exceeded our expectations," Thumm said.

Feuerstein had since moved to Heidelberg, where he and his group of researchers continued to collaborate with Thumm's group at K-State. Excited about the success of their model, they began to analyze the molecule's vibrational motion by breaking it down into its various frequencies. Each frequency being like a note in a chord, the frequencies told researchers how the protons were behaving. However, the frequency of these molecular vibrations is way above the audible range. The two researchers share an interest in music and had collaborated musically before. So when it came time to illustrate the revival, they decided the best way to do it was to scale the frequencies down to 1,000 Hertz, which is in the range at which the human ear hears best. "This way you can listen to the vibrations and hear the revival. In the same way sound is analyzed and decomposed, we decomposed the vibration with regard to the frequencies," Thumm said. Their result, a changing musical chord coupled with a movie illustrating the protons' vibrations can be heard and viewed at http://www.mpg.de/video/FilmundoAudio-KdM.wmv

Thumm said researchers hope to be able to do the same thing for more complex molecules like water or methane. Just as a C Major chord sounds different from a d minor chord, Thumm said other molecules also would have their own unique sound. Thumm and Feuerstein's most recent work was first published last fall in the Physical Review Letters. Their research was supported by the National Science Foundation, the U.S. Department of Energy and the Max-Planck Society. Thumm said such basic research supports the long-term goal of applying lasers to steer chemical reactions. The hope is to largely increase the efficiency of chemical reactions by enhancing desired reaction pathways with lasers, he said.

Adapted from materials provided by Kansas State University.



Read the rest of this entry »

Daily Science Journal (Feb. 10, 2008) — People taking a widely used group of drugs known as calcium channel blockers to treat high blood pressure also appear to be cutting their risk of Parkinson's disease, according to a new study.

The study involved 7,374 men and women over age 40. Half of the group had Parkinson's disease; the other half did not have Parkinson's disease. Among both groups, nearly half used high blood pressure medications, such as calcium channel blockers, ACE inhibitors, AT II antagonists and beta blockers.


The study found people who were currently long-term users of calcium channel blockers to treat high blood pressure lowered their risk of Parkinson's disease by 23 percent compared to people who didn't take the drugs. There was no such effect among people taking ACE inhibitors, AT II antagonists and beta blockers.

"Long-term use of calcium channel blockers was associated with a reduced risk of developing Parkinson's disease while no such association was seen for other high blood pressure medicines," said study author Christoph R. Meier, PhD, MSc, with University Hospital Basel in Switzerland.

Meier says more research is needed to determine why calcium channel blockers appear to protect against Parkinson's disease, whether this is indeed a causal association, and why the other high blood pressure medications do not offer a reduced risk.

This research was published in the February 6, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Adapted from materials provided by American Academy of Neurology.



Read the rest of this entry »

Daily Science Journal (Feb. 10, 2008) — Teenage fathers are at increased risk of having babies born with birth problems ranging from pre-term delivery or low birth weight, through to death in or near to the time of delivery, according to new research.*

In contrast, the study also found that older fathers, aged 40 and over, were not at increased risk of having babies affected by these problems. The results were independent of the age of the mother or other maternal factors that might be expected to have an impact on birth outcomes.

The research is the largest study on the effects of paternal age on adverse birth outcomes. The researchers, from the Ottawa Health Research Institute, Canada, used data from the National Center for Health Statistics for nearly all the births (99%) in the USA between 1995-2000 -- a cohort of more than 23.6 million births. From these, they looked at 2,614,966 singleton babies born live to married women without previous childbearing histories, aged between 20-29, where there was complete information on paternal age, race, maternal education, prenatal care, and gestational and birth weight.


They chose women aged between 20-29 because they were the least likely to be affected by fertility problems, some of which can have an impact on birth outcomes. Since it is already known that fathers aged between 20-29 have the lowest risk of adverse birth outcomes, the researchers used this age group (the reference group) to compare all the other age groups against.

Compared to the reference group and after adjusting for confounding factors (such as race, education, smoking and alcohol drinking during pregnancy, adequacy of prenatal care and the sex of the baby), babies born to teenage fathers (aged less than 20) were more likely to be born early (a 15% increased risk), have low birth weight (13% increased risk), be small for gestational age (17% increased risk), have a low Apgar score (13% increased risk) or to die within the first four weeks after birth (22% increased risk) or to die in the period from four weeks to one year after birth (41% increased risk), although in all cases the absolute risk of death remained less than 0.5% . Fathers aged 40 or over did not have an increased risk of these adverse birth outcomes.

One of the authors of the study, Professor Shi Wu Wen, senior scientist at the Ottawa Health Research Institute and professor at the University of Ottawa, said: "Our study indicated that being a teenage father was an independent risk factor for adverse birth outcomes, whereas advanced paternal age was not. The paternal influence of younger fathers on adverse birth outcomes clearly warrants further investigation, and may lead to a deeper understanding of the causes of such outcomes.

"Although the increased relative risks for most outcomes were small, the magnitude of the risks to society could be huge, given the number of births worldwide, if the increases we found are truly attributable to paternal age."

The study looked at babies born to fathers in seven age groups, from teenagers through to those aged 50 and over, and Prof Wen said this, together with the large size of the study and the limited age range of the mothers, meant that the findings were unlikely to be affected by chance or confounding factors. However, there was no information available on the socio-economic status and lifestyle of the fathers, and this could have an impact.

"The mechanisms by which being a teenage father may contribute to an increased risk of adverse birth outcomes are not clear," said Prof Wen. "Both biological and socio-economic status might play some roles in the observed findings."

Previous studies have shown that younger men can have lower sperm counts, semen volume, total numbers of spermatozoa and percentage of motile sperm. Immature sperm may be associated with adverse birth outcomes, possibly as a result of the abnormal formation of the placenta in the uterus (placentation).

"It is biologically plausible that paternal age might play a role in the risk of adverse birth outcomes associated with abnormal placentation," said Prof Wen.

However, there are also possible social explanations too. "Young fathers are more likely to come from economically disadvantaged families and to have lower educational attainment. Socio-economic factors such as education and occupation are known to be associated with a number of health outcomes. People from less affluent backgrounds are less likely to utilise prenatal care services, which is associated with an increased risk of adverse birth outcomes," explained Prof Wen.

Other social factors that might play a role, perhaps by adversely affecting the mother's health, include domestic violence, lack of financial or emotional support, paternal illicit drug use, smoking and alcohol drinking. "These are more prevalent in teenage fathers, and previous studies have found associations between paternal smoking and alcohol and adverse reproductive outcomes," he said.

Of the finding that older fathers were not more likely to have babies affected by adverse birth outcomes, Prof Wen said: "In our present study, we did not find an association between older fathers and the increased risk of adverse birth outcomes. We could not exclude the possibility that older fathers who married women aged 20-29 years without childbearing history might have a higher socioeconomic status than our control groups. The advantaged socioeconomic conditions might offset some biological risk of adverse birth outcomes associated with older fathers."

Prof Wen said he and his colleagues were planning a pre-conception study to look at various paternal and maternal factors that might have an effect on the health of babies, including paternal age.

*Paternal age and adverse birth outcomes: teenager or 40+, who is at risk? Human Reproduction. doi:10.1093/humrep/dem403.

Adapted from materials provided by European Society for Human Reproduction and Embryology, via EurekAlert!, a service of AAAS.



Read the rest of this entry »

Daily Science Journal (Feb. 10, 2008) — An international clinical trial has found that acyclovir, a common medication for treating herpes simplex virus-2 (HSV-2), the most common cause of genital herpes, does not reduce the risk of HIV infection when taken by people infected with HSV-2. Multiple studies have shown that people with HSV-2 have a higher risk of acquiring HIV. Researchers had hoped that acyclovir's ability to suppress the herpes virus, and its associated genital sores and breaks in the skin, could cut down on the likelihood of HIV being transmitted to a person with HSV-2 during sexual intercourse.

The Phase III clinical trial was led by the University of Washington in Seattle, in coordination with the HIV Prevention Trials Network, an international consortium funded by the National Institute of Allergy and Infectious Diseases (NIAID) in the National Institutes of Health. The findings were presented this week at the Conference on Retroviruses and Opportunistic Infections in Boston.


"The study was successful in answering the question of whether acyclovir could cut down on the risk of HIV acquisition for people infected with HSV-2," explained Dr. Connie Celum, the leader of the study and a UW professor of global health and medicine in the Division of Allergy and Infectious Disease and director of the International Clinical Research Center in the UW Department of Global Health. "We were hopeful that acyclovir would help reduce HIV acquisition in people with HSV-2. Though the study did not find that acyclovir helped with HIV acquisition, we did find that it reduced genital ulcers associated with HSV-2. Now we need to continue our research on the mechanisms through which HSV-2 acts as a risk factor for HIV, and how we might be able to use that knowledge to reduce the spread of HIV."

HSV-2 is one of the most common sexually transmitted infections worldwide and is especially prevalent in areas with high rates of HIV infection. Most people who are infected with HSV-2 do not know they have the virus because symptoms can be mild or absent. In some infected individuals, the virus can produce recurring genital herpes, a condition characterized by sores and breaks in the skin of the genital region. An active HSV-2 infection also attracts immune-system cells called CD-4 T-cells to the genital region, and HIV easily attaches to this type of cell. Multiple studies have shown that people with HSV-2 have a two-fold increase in their risk of acquiring HIV.

This study followed up on those results to test the theory that suppressing HSV-2 could cut down on HIV acquisition. It was launched in 2003, and with nine study sites in Peru, South Africa, Zambia, Zimbabwe, and the United States, it was the largest study yet of herpes suppression. There were 3,277 people with HSV-2 initially enrolled in the study, 105 people excluded, and 3,172 people included in the final analysis. Volunteers in Peru and the United States were HSV-2-infected men who have sex with men, and volunteers in Africa were HSV-2-infected women.

Half of the participants were randomly assigned to receive either a placebo or a standard daily dose of acyclovir, 400 mg twice a day. The study was double-blinded, meaning that neither participants nor care providers knew which treatment the participants were receiving. Both the placebo and treatment groups received standard HIV-prevention treatment, which includes being supplied with condoms and given extensive counseling on how to reduce the risk of HIV infection.

Researchers found that there was a 3.9 percent HIV incidence rate, a total of 75 cases, in participants who received acyclovir suppression, and a 3.3 percent HIV incidence rate, or 64 cases, in the placebo group. The difference between the groups was not statistically significant. The acyclovir treatment did succeed in reducing genital ulcers -- participants in the treatment group had a 37 percent reduction in genital ulcer incidence, and a significantly lower proportion of ulcers due to HSV-2.

"The study answered the scientific questions it was designed to answer," says Dr. Anna Wald, a UW professor of medicine and epidemiology who also helped lead the study. "The sites were able to recruit and retain a large number of volunteers, who maintained a high level of adherence to the twice-daily drug regimen. While we are disappointed with the results, the study was well-conducted and provides a clear answer about using acyclovir to reduce the risk of becoming HIV-infected."

The study participants have been informed of the findings and are being counseled on the continued need to avoid HIV exposure. Volunteers who became infected with HIV during the trial have been referred for appropriate medical care and treatment.

The study was supported by NIAID, and the acyclovir was supplied by GlaxoSmithKline. The HIV Prevention Trials Network is led by Family Health International, the network laboratory of Johns Hopkins University, and the Statistical Center for HIV/AIDS Research and Prevention at the Fred Hutchinson Cancer Research Center in Seattle. The study was conducted at the following sites: Iquitos, Lima and Pucallpa, in Peru; Johannesburg, South Africa; New York, San Francisco, and Seattle, in the United States; Lusaka, Zambia; and Harare, Zimbabwe.

Adapted from materials provided by University Of Washington.



Read the rest of this entry »

Daily Science Journal (Feb. 9, 2008) — Natural flyers like birds, bats and insects outperform man-made aircraft in aerobatics and efficiency. University of Michigan engineers are studying these animals as a step toward designing flapping-wing planes with wingspans smaller than a deck of playing cards.

Flapping flight is inherently unsteady, but that's why it works so well. Birds, bats and insects fly in a messy environment full of gusts traveling at speeds similar to their own. Yet they can react almost instantaneously and adapt with their flexible wings. (Credit: iStockphoto/Steve Byland)

A Blackbird jet flying nearly 2,000 miles per hour covers 32 body lengths per second. But a common pigeon flying at 50 miles per hour covers 75. The roll rate of the aerobatic A-4 Skyhawk plane is about 720 degrees per second. The roll rate of a barn swallow exceeds 5,000 degrees per second.


Select military aircraft can withstand gravitational forces of 8-10 G. Many birds routinely experience positive G-forces greater than 10 G and up to 14 G.

“Natural flyers obviously have some highly varied mechanical properties that we really have not incorporated in engineering,” said Wei Shyy, chair of the Aerospace Engineering department and an author of the new book “The Aerodynamics of Low Reynolds Number Flyers.”

“They’re not only lighter, but also have much more adaptive structures as well as capabilities of integrating aerodynamics with wing and body shapes, which change all the time,” Shyy said. “Natural flyers have outstanding capabilities to remain airborne through wind gusts, rain, and snow.” Shyy photographs birds to help him understand their aerodynamics.

Pressure generated during flight cause the flapping wings to deform, he explained. In turn, the deformed wing tells the air that the wing shape is different than it appears in still air. If appropriately handled, this phenomenon can delay stall, enhance stability and increase thrust.

Flapping flight is inherently unsteady, but that’s why it works so well. Birds, bats and insects fly in a messy environment full of gusts traveling at speeds similar to their own. Yet they can react almost instantaneously and adapt with their flexible wings.

Shyy and his colleagues have several grants from the Air Force totaling more than $1 million a year to research small flapping wing aircraft. Such aircraft would fly slower than their fixed wing counterparts, and more importantly, they would be able to hover and possibly perch in order to monitor the environment or a hostile area. Shyy’s current focus is on the aerodynamics of flexible wings related to micro air vehicles with wingspans between 1 and 3 inches.

“These days, if you want to design a flapping wing vehicle, you could build one with trial and error, but in a controlled environment with no wind gusts,” Shyy said. “We are trying to figure out how to design a vehicle that can perform a mission in an uncertain environment. When the wind blows, how do they stay on course?”

A dragonfly, Shyy says, has remarkable resilience to wind, considering how light it is. The professor chalks that up to its wing structure and flight control. But the details are still questions.

“We’re really just at the beginning of this,” Shyy said.

Shyy is the Clarence L. "Kelly" Johnson Collegiate Professor of Aerospace Engineering. Other authors of the book, “Aerodynamics of Low Reynolds Number Flyers” are: U-M research scientists Yongsheng Lian, Jian Tang and Dragos Viieru, and Hao Liu, professor of Biomechanical Engineering at Chiba University in Japan.

Other collaborators on this research include professors Luis Bernal, Carlos Cesnik and Peretz Friedmann of the University of Michigan; Hao Liu of Chiba University in Japan; Peter Ifju, Rick Lind and Larry Ukeiley of University of Florida, and Sean Humbert of University of Maryland.

Adapted from materials provided by University of Michigan.



Read the rest of this entry »

Daily Science Journal (Feb. 9, 2008) — Babies recently treated with infant personal care products such as lotion, shampoo, and powder, were more likely to have manmade chemicals called phthalates in their urine than other babies, according to University of Washington and Seattle Children's Hospital Research Institute study appearing in the February issue of the journal Pediatrics. Phthalates (pronounced "thah-lates") are added to many personal care and cosmetic products, as well many common household plastic and vinyl products, and some studies suggest they may affect reproductive development in humans.

Babies recently treated with infant personal care products such as lotion, shampoo, and powder, were more likely to have manmade chemicals called phthalates in their urine than other babies. (Credit: iStockphoto/Roman Barelko)

Animal-based studies of phthalates have found that the synthetic chemicals can harm reproductive system development, and studies in humans have found that prenatal exposure or exposure through breast milk can alter hormone concentrations. Early-childhood exposure has not been extensively studied, so additional research is needed to determine if phthalate exposure can indeed cause reproductive development problems or other adverse effects in infants.


In this study, the researchers set out to see if use of personal care products was associated with urine phthalate concentrations. To accomplish this, they collected urine samples from 163 infants aged 2 months to 28 months, and measured the levels of nine different phthalates in those urine samples. They also had the babies' mothers fill out questionnaires on their use of infant personal care products in the past 24 hours.

When they cross-referenced the data, they found that the use of baby powder, lotion, and shampoo were each strongly associated with higher phthalate levels in the urine. The use of baby wipes and diaper cream were not strongly associated with increased levels of phthalates. The scientists also found that every baby had detectable levels of at least one phthalate in their urine, and about 81 percent of the infants had detectable levels of seven or more phthalates. Babies who were 8 months old or younger had stronger associations between product use and phthalate concentrations, as did babies whose mothers used more infant personal care products.

"We found that infant exposure to phthalates is widespread, and that exposure to personal care products applied onto the skin may be an important source," said the study's lead author, Sheela Sathyanarayana, an acting assistant professor of pediatrics at the UW School of Medicine and a researcher with Seattle Children's Hospital Research Institute. "This is troubling, because phthalate exposure in early childhood has been associated with altered hormone concentrations as well as increased allergies, runny nose, and eczema. Babies may be more at risk than children or adults because their reproductive, endocrine, and immune systems are still developing."

Parents who want to decrease their baby's exposure to phthalates should limit the amount of baby care products used on the infant, and apply lotions or powders only if medically indicated. Since phthalates are also found in many household plastic products, like plastic food containers, parents can also stop putting plastics in the microwave oven and use glass alternatives whenever possible. Phthalate-free cosmetics and personal care products are also available.

This research project was supported by grants from the U.S. Environmental Protection Agency, the National Institutes of Health, and the National Institute of Environmental Health Sciences. The project included researchers from the UW Departments of Occupational and Environmental Health Sciences, Pediatrics, and Biostatistics; the Seattle Children's Hospital Research Institute; the Centers for Disease Control and Prevention; and the University of Rochester School of Medicine and Dentistry.

Adapted from materials provided by University Of Washington.



Read the rest of this entry »

Daily Science Journal (Feb. 9, 2008) — A new energy-capturing knee brace can generate enough electricity from walking to operate a portable GPS locator, a cell phone, a motorized prosthetic joint or an implanted neurotransmitter, research involving the University of Michigan shows.

The biomechanical energy harvester includes an aluminum chassis and generator mounted on a customized orthopaedic knee brace. The device weighs 3.5 lbs. (Credit: Greg Ehlers/Simon Fraser University)

The wearable mechanism works much like regenerative braking charges a battery in some hybrid vehicles, said Arthur Kuo, an associate professor of mechanical engineering at U-M and an author of the paper.*

Regenerative brakes collect the kinetic energy that would otherwise be dissipated as heat when a car slows down. This knee brace harvests the energy lost when a human brakes the knee after swinging the leg forward to take a step.


Kuo, who called the device "a cocktail-napkin idea," says knee joints are uniquely suited for this endeavor.

"There is power to be harvested from various places in the body, and you can use that to generate electricity. The knee is probably the best place," he said. "During walking, you dissipate energy in various places, when your foot hits the ground, for example. You have to make up for this by performing work with your muscles.

"The body is clever," Kuo said. "In a lot of places where it could be dissipating energy, it may actually be storing it and getting it back elastically. Your tendons act like springs. In many places, we're not sure whether the energy is really being dissipated or you're just storing it temporarily. We believe that when you're slowing down the knee at the end of swinging the leg, most of that energy normally is just wasted."

The scientists tested the knee brace on six men walking leisurely on a treadmill at 1.5 meters per second, or 2.2 miles per hour. They measured the subjects' respiration to determine how hard they were working. A control group wore the brace with the generator disengaged to measure how the weight of the 3.5-pound brace affected the wearer.

In the mode in which the brace is only activated while the knee is braking, the subjects required less than one watt of extra metabolic power for each watt of electricity they generated. A typical hand-crank generator, for comparison, takes an average of 6.4 watts of metabolic power to generate one watt of electricity because of inefficiencies of muscles and generators.

"We've demonstrated proof of concept," Kuo said. "The prototype device is bulky and heavy, and it does affect the wearer just to carry. But the energy generation part itself has very little effect on the wearer, whether it is turned on or not. We hope to improve the device so that it is easier to carry, and to retain the energy-harvesting capabilities."

A lighter version would be helpful to hikers or soldiers who don't have easy access to electricity. And the scientists say similar mechanisms could be built into prosthetic knees other implantable devices such as pacemakers or neurotransmitters that today require a battery, and periodic surgery to replace that battery.

"A future energy harvester might be implanted along with such a device and generate its own power from walking," Kuo said.

The paper "Biomechanical Energy Harvesting: Generating Electricity During Walking with Minimal User Effort" is published in the Feb. 8 issue of the journal Science. Authors include researchers from Simon Fraser University in Canada and the University of Pittsburgh, in addition to U-M.

Adapted from materials provided by University of Michigan.



Read the rest of this entry »

Daily Science Journal (Feb. 9, 2008) — Less sleep can increase a child’s risk of being overweight or obese, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health. Their analysis of epidemiological studies found that with each additional hour of sleep, the risk of a child being overweight or obese dropped by 9 percent.

“Our analysis of the data shows a clear association between sleep duration and the risk for overweight or obesity in children. The risk declined with more sleep,” said Youfa Wang, MD, PhD, senior author of the study and associate professor with the Bloomberg School’s Center for Human Nutrition. “Desirable sleep behavior may be an important low cost means for preventing childhood obesity and should be considered in future intervention studies. Our findings may also have important implications in societies where children do not have adequate sleep due to the pressure for academic excellence and where the prevalence of obesity is rising, such as in many East Asian countries.”


“The influence of sleep quality on obesity risk is another important area where future research is needed,” added Xiaoli Chen, MD, PhD, the study’s lead author and a former postdoctoral fellow at the Bloomberg School.

For the study, Wang, Chen and colleague May A. Beydoun, also a postdoctoral fellow at the Bloomberg School, reviewed 17 published studies on sleep duration and childhood obesity and they analyzed 11 of them in their meta-analysis.

The recommended amount of daily sleep varied between studies analyzed and with children’s age. It is recommended that children under age 5 should sleep for 11 hours or more per day, children age 5 to10 should sleep for 10 hours or more per day, and children over age 10 should sleep at least 9 hours per day.

The results of the analysis showed that children with the shortest sleep duration had a 92 percent higher risk of being overweight or obese compared to children with longer sleep duration. For children under age 5, shortest sleep duration meant less than 9 hours of sleep per day. For children ages 5 to 10 it meant less than 8 hours of sleep per day and less than 7 hours of sleep per day for children over 10. The association between increased sleep and reduced obesity risk was strongly associated with boys, but not in girls.

The results are published in the February 2008 edition Obesity, the journal of The Obesity Society. “Is Sleep Duration Associated with Childhood Obesity? A Systematic Review and Meta-analysis” was written by Xiaoli Chen, May A. Beydoun and Youfa Wang.

The study was supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases, the U.S. Department of Agriculture and the Johns Hopkins Bloomberg School of Public Health.

Adapted from materials provided by Johns Hopkins University Bloomberg School of Public Health.



Read the rest of this entry »